Mixture of human papillomavirus virus-like particles

Details Mixture of human papillomavirus virus-like particles Mixture of human papillomavirus virus-like particles

2008-07-18

2010-10-19

Salimi, Ali R. (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Virus or component thereof

C435S006120

Reexamination Certificate

active

07815915

ABSTRACT:
The present invention relates to a vaccine composition comprising VLPs containing L1 proteins or functional L1 protein derivatives from HPV 16, HPV 18, HPV 31 and HPV 45 genotypes.

REFERENCES:
patent: 5855891 (1999-01-01), Lowy et al.
patent: 6066324 (2000-05-01), Gissmann et al.
patent: 6245568 (2001-06-01), Volkin et al.
patent: 6251678 (2001-06-01), Volkin et al.
patent: 6908613 (2005-06-01), Wilson et al.
patent: 6936255 (2005-08-01), Wettendorff
patent: 7101560 (2006-09-01), Wettendorff
patent: 7205125 (2007-04-01), Castillo et al.
patent: 7217419 (2007-05-01), Wettendorff
patent: 7279306 (2007-10-01), Schlegel et al.
patent: 7416846 (2008-08-01), Wettendorff
patent: 2004/0121465 (2004-06-01), Robinson
patent: 2004/0131638 (2004-07-01), Debrus et al.
patent: 2005/0123562 (2005-06-01), Wettendorff
patent: 689454 (1997-09-01), None
patent: WO 95/17209 (1995-06-01), None
patent: WO 95/31532 (1995-11-01), None
patent: WO 96/11274 (1996-04-01), None
patent: WO 99/13056 (1999-03-01), None
patent: WO 99/45957 (1999-09-01), None
patent: WO 99/50424 (1999-10-01), None
patent: WO 00/09671 (2000-02-01), None
patent: WO 00/09699 (2000-02-01), None
patent: WO 00/23105 (2000-11-01), None
patent: WO01/17551 (2001-03-01), None
patent: WO 01/17551 (2001-03-01), None
patent: WO01/97840 (2001-12-01), None
patent: WO03/077942 (2003-09-01), None
patent: WO 2004/056389 (2004-07-01), None
patent: WO2005/032586 (2005-04-01), None
Giuliano, et al. “Human papillomavirus infection at the United States-Mexico Border: Implications for cervical cancer prevention and control”Cancer Epidemiology Biomarkers&Prevention, 2001, 10(11), pp. 1129-1136.
Palker, et al. “Antibody, cytokine and cytotoxic T lymphocyte responses in chimpanzees immunized with human papillomavirus virus-like particles”Vaccine, Butterworth Scientific, 2001, 19(27), pp. 3733-3743.
Roden, et al. “Assesment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition”J of Virology, The American Society for Microbiology, 1996, 70(5), pp. 1996-2005.
Wheeler, “Preventive vaccines for cervical cancer”Salud Publica de Mexico, 1997, 39(4), pp. 283-287.
U.S. Appl. No. 09/807,657.
U.S. Appl. No. 10/540,099.
U.S. Appl. No. 11/477,879.
Bachtiary, et al, Impact of multiple HPV infection on response to treatment and survival in pts. receiving radical radiotherapy for cervical cancer, International Journal of Cancer, Journal International Du Cancer, US, Nov. 20, 2002, vol. 102, No. 3, pp. 237-243.
Bass, et al, Progress in the search of a vaccine against human papilloma virus, IAVI Report Oct./Nov. 2002, Online, Oct. 10, 2002, retrieved from the internet—www.aegis.com/pubs/iavi/2002/IAVI2002-1003.html, retrieved on Apr. 21, 2004.
Bosch, et al., Prevalence of human papillomavirus in cervical cancer: a worldwide perspective, J. Nat. Canc. Inst. vol. 87, No. 11, p. 796-802 (1995).
Breitburd et al., Immunization with Virus-Like Particles from Cottontail Rabbit Papillomavirus (CRPV) Can Protect Against Experimental CRPV Infection, Journal of Virology, vol. 69, p. 3959-3963(1995).
Brown, et al, A dose ranging study of the safety and immunogenicity profiles of a quadrivalent HPV (types 6, 11, 16 and 18) L1 VLP candidate vaccine in young healthy women, Abstract 0-51, 19thInternational Papillomavirus Conference, Sep. 2001, Florianopolis, Brazil.
Carter, et al., Comparison of human papillomavirus Types 16, 18, and 6 capsid antibody responses following incident infection, The Journal of Infectious Diseases Society of America, vol. 181, p. 19111-19119 (2000).
Chan, et al., Analysis of genomic sequences of 95 papillomavirus types: Uniting typing, phylogeny, and taxonomy, Journal of Virology, vol. 69, No. 5, pp. 3074-3083 (1995).
Chan, et al., Phylogenetic analysis of 48 papillomavirus types and 28 subtypes and variants: a showcase for the molecular evolution of DNA viruses, J. Virology, vol. 66, No. 10, p. 5714-5725 (1992).
Clifford, et al., Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis, British J. of Cancer, vol. 88, p. 63-73 (2003).
Coutlee, et al., Comparison between vaginal tampon and cervicovaginal lavage specimen collection for detection of human papillomavirus DNA by the polymerase chain reaction, Journal of Medical Virology, vol. 51, p. 42-47 (1997).
Garland, et al., An evaluation of noninferiority in antibody response to human papillomavirus (HPV) Type 16 in subjects vaccinated with monovalent (HPV 16) and quadrivalent (HPV 6, 11, 16, 18) L1virus-like particle vaccines, published online ahead of print on Apr. 11, 2007, Clin, Vaccine Immuno. Doi:10.1128/CVI.00478-06 (2007).
Garland, et al., Noninferiority of antibody aesponse to human papillomavirus Type 16 in subjects vaccinated with monovalent and quadrivalent L1virus-like particle vaccines, Clinical and Vaccine Immunology, vol. 14, No. 6, pa 792-795 (2007).
Giroglou et al., “Immunological analyses of human papillomavirus capsids”, Vaccine, vol. 19, No. 13-14, 2001, pp. 1783-1793 (2001).
Harper, Cervarix™ HPV-16/18 L1 VLP AS04 vaccine: sustained antibody levels though 5.5 years against HPV-16 and 18, presentation ESGO, Oct. 31, 2007.
Harper, et al., Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial, The Lancet, vol. 367, p. 1247-1255 (2006).
Harro, et al., Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine, J. of the National Cancer Institute, vol. 93, No. 4, p. 284-292 (2001).
Koutsky, et al., A controlled trial of a human papillomavirus type 16 vaccine, N. Engl. J. Med., vol. 347, No. 21, p. 1645-1651 (2002).
Mach, et al., Disassembly and reassembly of yeast-derived recombinant human papillomavirus virus-like particles (HPV VLPs), J. of Pharmaceutical Sciences, vol. 95, No. 10, p. 2195-2206 (2006).
Moore, et al., Absence of canine oral papillomavirus DNA following prophylactic L1 particle-mediated immunotherapeutic delivery vaccination, Journal of General Virology 83:2299-2301,(2002).
Paavonen, et al., Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial, The Lancet, vol. 369, p. 2161-2170 (2007).
Schiller et al., Papillomavirus-like particles and HPV vaccine development, Seminars in Cancer Biology, vol. 7, No. 6, pp. 373-382 (1996).
Schiller, et al, Papillomavirus-like particle base vaccines: cervical cancer and beyond, Expert Opinion on Biological Therapy, Ashley, London, GB, vol. 1, No. 4, p. 571-581 (2001).
Shi, et al., GARDASIL®: Prophylactic human papillomavirus vaccine development—from bench top to bed-side, Clinical Pharmacology & Therapeutics, vol. 81, No. 2, p. 259-264 (2007).
Steller, et al., Cervical cancer vaccines: progress and prospects, Journal of the Society for Gynecologic Investigation, US, Sep., Oct. 2002, vol. 9, No. 5, pp. 254-264 (2002).
Suzich, et al., Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas, Proceedings of the National Academy of Sciences of USA, National Academy of Science, vol. 92, p. 11553-11557 (1995).
Thompson, et al., Immunogenicity & reactogenicity of a recombinant HPV6 fusion protein vaccine adjuvanted with monophosphoryl lipid A, Biochemical Society Transactions, vol. 274S p. 25 (1997).
Van Ranst, et al., Phylogenetic classification of human papillomaviruses: correlation with clinical manifestations, J. of General Virology, vol. 73, p. 2653-2660 (1992).
Villa., et al, A dose-ranging safety and immunogenicity study of a quadrivalent HPV (type 6/11/16/18) L1 VLP vaccine in women, HPV Clinical Workshop & 20thInternational Papillomavirus Conference 2002, Oct. 4-9, 2002, Paris, Institute Pasteur.
White, et al., “In Vitro Infection and Type-Restricted Antibo

Affiliated with

Also associated with

Rating

Mixture of human papillomavirus virus-like particles does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Mixture of human papillomavirus virus-like particles, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mixture of human papillomavirus virus-like particles will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4236247